Holen Sie sich die Stockscreener-App
75.34
1.71%
1.27
Vorhandelsmarkt:
76.40
1.06
+1.41%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$74.07
Offen:
$74.11
24-Stunden-Volumen:
2.77M
Relative Volume:
0.60
Marktkapitalisierung:
$233.66B
Einnahmen:
$56.50B
Nettoeinkommen (Verlust:
$8.30B
KGV:
28.38
EPS:
2.655
Netto-Cashflow:
$8.18B
1W Leistung:
+1.15%
1M Leistung:
+5.92%
6M Leistung:
+1.22%
1J Leistung:
-8.70%
1-Tages-Spanne:
$74.04
$75.37
1-Wochen-Bereich:
$73.11
$75.37
52-Wochen-Spanne:
$61.24
$87.67
Astrazeneca PLC Stock (AZN) Company Profile
Firmenname
Astrazeneca PLC
Sektor
Branche
Telefon
44 20 3749 5000
Adresse
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Vergleichen Sie AZN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca PLC
|
75.34 | 229.65B | 56.50B | 8.30B | 8.18B | 2.655 |
Astrazeneca PLC Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca PLC Aktie (AZN) Neueste Nachrichten
AstraZeneca, Stockholders Far Apart In Merger Damages Tally - Law360
AstraZeneca’s Phase 3 Study on Anifrolumab: A Potential Breakthrough for Lupus Treatment - TipRanks
AstraZeneca’s Phase III Study on Dato-DXd in Advanced Breast Cancer: Key Insights for Investors - TipRanks
AstraZeneca’s CRT Study in Russia: Implications for Lung Cancer Treatment - TipRanks
AstraZeneca’s iCaReMe Global Registry: A Game Changer in Real-World Data Collection - TipRanks
AstraZeneca’s Latest Study on Balcinrenone/Dapagliflozin: Key Insights for Investors - TipRanks
AstraZeneca’s Real-World Study on NSCLC Drugs: Key Insights for Investors - The Globe and Mail
AstraZeneca’s Real-World Study on Tezepelumab: Implications for Severe Asthma Treatment - TipRanks
AstraZeneca’s New CKD Study: A Strategic Move in the Chinese Market - TipRanks
AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer in Cardiovascular Health - TipRanks
AstraZeneca Sees Slight Change in Voting Rights by Capital Group - TipRanks
Ascites Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company - The Globe and Mail
Revna Biosciences and AstraZeneca Increase Access to Lung Cancer Treatment in Ghana - sg.finance.yahoo.com
Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts - Benzinga
AstraZeneca’s PROGRESS-CKD Study: A New Frontier in Hypertension and Kidney Disease Research - TipRanks
AstraZeneca’s DESTINY-Lung03: A Promising Phase Ib Study in NSCLC - TipRanks
AstraZeneca’s Phase II Study on AZD9291: A Promising Update for NSCLC Treatment - TipRanks
AstraZeneca’s AZD9291 Trial: A New Hope for Lung Cancer Treatment? - TipRanks
AstraZeneca: Great Portfolio, But Not A Great Price (NASDAQ:AZN) - Seeking Alpha
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca’s CARDIO-TTRansform Study: A Potential Game-Changer for ATTR CM Treatment - The Globe and Mail
AstraZeneca’s NeoCOAST-2 Study: A New Frontier in Lung Cancer Treatment - The Globe and Mail
AstraZeneca’s Andexanet Alfa Study: Real-World Insights for Investors - The Globe and Mail
AstraZeneca’s Real-World Study on Koselugo: Key Insights for Investors - The Globe and Mail
AstraZeneca’s Phase II Study on Olaparib in Ovarian Cancer: A Market Perspective - The Globe and Mail
AstraZeneca’s Anifrolumab Study: A Potential Game-Changer in Inflammatory Myopathies - TipRanks
AstraZeneca’s Promising Phase 2b Study on AZD2693 for NASH: Key Insights for Investors - TipRanks
AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer for CKD Treatment - TipRanks
AstraZeneca’s Latest NSCLC Study: A Potential Game-Changer? - The Globe and Mail
AstraZeneca’s AZD6234 Study: A Potential Game-Changer for Renal Impairment Treatment - TipRanks
AstraZeneca’s Phase I Study on AZD4954: A Potential Game-Changer in Cardiovascular Treatment - The Globe and Mail
AstraZeneca’s Anifrolumab Study: Real-world Insights into SLE Treatment - TipRanks
AstraZeneca’s ARTEMIDE-Lung03 Study: A New Frontier in NSCLC Treatment - TipRanks
AstraZeneca’s PANGEIA-2 Study: Unveiling New Insights in Breast Cancer Mutations - TipRanks
AstraZeneca’s TROPION-Lung05 Study: A New Hope for Advanced NSCLC - TipRanks
AstraZeneca’s New Trial: Exploring AZD8421 for Advanced Cancers - TipRanks
AstraZeneca’s Real-World Study on mCRPC Treatment: Key Insights for Investors - TipRanks
AstraZeneca’s New Study on TDC Treatment for mNSCLC: Key Insights for Investors - TipRanks
Inside AstraZeneca’s long-term strategy in lung cancer - BioPharma Dive
Swedish Shares in North America – AstraZeneca Rises 1.1 Percent - MarketScreener
AstraZeneca’s Promising Phase II Study on AZD6234: A Potential Game-Changer for Type 2 Diabetes - TipRanks
AstraZeneca’s New COPD Study: Potential Market Shifts Ahead - TipRanks
Amgen and AstraZeneca’s HORIZON Study: A New Hope for Pediatric Asthma - TipRanks
AstraZeneca’s Promising Study on Durvalumab for Advanced Biliary Tract Cancers - TipRanks
AstraZeneca’s New Study on AZD5004: Potential Market Implications - TipRanks
AstraZeneca’s Phase III Study on Advanced Liver Cancer: Key Insights for Investors - TipRanks
AstraZeneca’s Promising Study on Volrustomig for Mesothelioma: Key Insights for Investors - TipRanks
AstraZeneca’s TITANium Study: A New Hope for B-Cell Malignancies? - TipRanks
AstraZeneca’s New Phase III Study: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks
AstraZeneca’s Phase 1 Study on AZD9833: A New Hope for Advanced Breast Cancer - TipRanks
Finanzdaten der Astrazeneca PLC-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):